[{"address1": "2000 Sierra Point Parkway", "address2": "Suite 400", "city": "Brisbane", "state": "CA", "zip": "94005", "country": "United States", "phone": "415 798 8589", "website": "https://www.tempesttx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.", "fullTimeEmployees": 17, "companyOfficers": [{"maxAge": 1, "name": "Mr. Stephen R. Brady J.D., LLM", "age": 53, "title": "CEO, President & Director", "yearBorn": 1970, "fiscalYear": 2022, "totalPay": 740950, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Samuel  Whiting M.D., Ph.D.", "age": 57, "title": "Executive VP & Chief Medical Officer", "yearBorn": 1966, "fiscalYear": 2022, "totalPay": 591225, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Nicholas  Maestas", "age": 43, "title": "VP of Strategy & Finance and Secretary", "yearBorn": 1980, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Justin  Trojanowski", "age": 35, "title": "Corporate Controller, Treasurer & Principal Accounting Officer", "yearBorn": 1988, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Lindsay  Young", "title": "Head of Human Resources", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sharon  Sakai Ph.D., RAC", "title": "Head of Regulatory & Quality", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 2, "previousClose": 3.91, "open": 3.92, "dayLow": 3.89, "dayHigh": 5.9, "regularMarketPreviousClose": 3.91, "regularMarketOpen": 3.92, "regularMarketDayLow": 3.89, "regularMarketDayHigh": 5.9, "beta": -2.777, "forwardPE": -3.5555556, "volume": 16672930, "regularMarketVolume": 16672930, "averageVolume": 683621, "averageVolume10days": 642490, "averageDailyVolume10Day": 642490, "marketCap": 120724480, "fiftyTwoWeekLow": 0.17, "fiftyTwoWeekHigh": 9.77, "fiftyDayAverage": 3.7871, "twoHundredDayAverage": 2.647115, "currency": "USD", "enterpriseValue": 63763416, "floatShares": 17774703, "sharesOutstanding": 22192000, "sharesShort": 766843, "sharesShortPriorMonth": 870367, "sharesShortPreviousMonthDate": 1707955200, "dateShortInterest": 1710460800, "sharesPercentSharesOut": 0.0346, "heldPercentInsiders": 0.03159, "heldPercentInstitutions": 0.29328, "shortRatio": 1.37, "shortPercentOfFloat": 0.0433, "impliedSharesOutstanding": 22192000, "bookValue": 1.214, "priceToBook": 4.4810543, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -29491000, "trailingEps": -1.91, "forwardEps": -1.53, "lastSplitFactor": "1:15", "lastSplitDate": 1624838400, "enterpriseToEbitda": -2.216, "52WeekChange": 0.70000005, "SandP52WeekChange": 0.28136122, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "TPST", "underlyingSymbol": "TPST", "shortName": "Tempest Therapeutics, Inc.", "longName": "Tempest Therapeutics, Inc.", "firstTradeDateEpochUtc": 1624887000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "d54d822e-cd83-39cb-b46d-5c9b6edb9502", "messageBoardId": "finmb_552715229", "gmtOffSetMilliseconds": -14400000, "currentPrice": 5.44, "targetHighPrice": 47.0, "targetLowPrice": 8.0, "targetMeanPrice": 18.6, "targetMedianPrice": 13.0, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 5, "totalCash": 39230000, "totalCashPerShare": 1.768, "ebitda": -28776000, "totalDebt": 20661000, "quickRatio": 4.169, "currentRatio": 4.289, "debtToEquity": 77.185, "returnOnAssets": -0.37307, "returnOnEquity": -1.31424, "freeCashflow": -17474750, "operatingCashflow": -27357000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-02"}]